Gossamer Bio Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 11c
November 12, 2019 4:39 PM ESTGossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.11 worse than the analyst estimate of ($0.69).
Since the beginning of the third quarter, we have realized substantial progress advancing our diverse pipeline of four clinical-stage programs, said Sheila Gujrathi, M.D., Co-Founder and Chief Executive... More
